SUPERNUS PHARMACEUTICALS, INC. SUPN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.

The Company was incorporated in Delaware, commenced operations in 2005, became publicly traded in 2012, and is listed on the NASDAQ Stock Exchange under the ticker symbol SUPN. Our principal executive offices are located in Rockville, Maryland. Our extensive expertise in product development has been built over the past 30 years: initially as a stand-alone development organization; then, as a United States (U.S.) subsidiary of Shire Plc (Shire, a subsidiary of Takeda Pharmaceutical Company Ltd.); then upon our acquisition of substantially all of the assets of Shire Laboratories, Inc. in 2005, as Supernus Pharmaceuticals, Inc.

Last close 40.70 2026-10-23
Market cap $2.37B 2026-06-30 share count
52-week range 37.54 - 59.68

Valuation FY2025 figures against the last close

P/S3.3x
P/E—
P/FCF51.4x
EV/EBITDA80.8x
Dividend yield—
Diluted EPS-0.68

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $719.0M$661.8M$607.5M$667.2M$579.8M$520.4M$392.8M$408.9M$302.2M$215.0M
Cost of revenue $74.6M$77.9M$83.8M$87.2M—$52.5M$16.7M$15.4M$15.2M$12.0M
Gross profit $644.4M$583.9M$523.7M$580.0M—$467.9M$376.1M$393.5M$287.0M$203.0M
R&D $106.2M$108.8M$91.6M$74.6M$90.5M$76.0M$69.1M$89.2M$49.6M$42.8M
SG&A $485.6M$321.6M$336.4M$377.2M$304.8M$200.7M$153.2M$154.7M$137.9M$106.0M
Total operating expenses $781.2M$580.2M$612.8M$621.1M$493.7M$346.7M$244.2M$264.5M$202.7M$160.8M
Operating income -$62.3M$81.7M-$5.3M$46.1M$86.0M$173.7M$148.6M$144.4M$99.5M$54.2M
Interest expense $0$0$2.4M$7.1M$19.7M$19.4M$18.2M$13.8M$134.0K$543.0K
Pre-tax income -$49.0M$97.9M$2.8M$60.7M$73.2M$168.6M$147.5M$140.2M$100.6M$50.4M
Income tax $10.5M$24.0M$1.5M$32.0K$19.8M$41.7M$34.4M$29.2M$43.3M$40.9M
Net income -$38.6M$73.9M$1.3M$60.7M$53.4M$127.0M$113.1M$111.0M$57.3M$91.2M
EPS, basic -0.681.340.021.131.012.412.162.131.131.84
EPS, diluted -0.681.320.021.040.982.362.102.051.081.76
Shares, diluted (wtd. avg.) 56.5M56.0M55.5M61.7M54.4M53.7M53.8M54.1M53.3M51.7M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $128.4M$69.3M$75.1M$93.1M$203.4M$288.6M$181.4M$192.2M$100.3M$66.4M
Short-term investments ———$368.2M$136.2M$133.9M$165.7M$163.8M$39.7M$23.7M
Receivables $187.8M$142.1M$144.2M$165.5M$148.9M$140.9M$87.3M$102.9M$67.2M$41.5M
Inventory $112.5M$54.3M$77.4M$91.5M$86.0M$48.3M$26.6M$25.7M$16.3M$16.8M
Total current assets $644.2M$686.1M$493.1M$734.2M$601.6M$630.4M$472.6M$493.5M$228.5M$151.4M
Property, plant and equipment $10.5M$11.5M$13.5M$15.2M$17.0M$37.8M$17.1M$4.1M$5.1M$4.3M
Goodwill $124.9M$117.0M$117.0M$117.0M$117.5M$77.9M$0———
Other intangibles $569.5M$521.9M$599.9M$702.5M$784.7M$364.3M$24.8M$31.4M$36.0M$36.4M
Total assets $1.45B$1.37B$1.28B$1.70B$1.69B$1.50B$1.16B$977.8M$424.5M$309.6M
Accounts payable $2.7M$4.6M$2.0M$10.5M$9.3M$6.1M$10.1M$3.2M$6.8M$8.1M
Total current liabilities $338.2M$292.4M$290.2M$688.0M$315.4M$245.1M$160.6M$161.4M$123.0M$80.7M
Total liabilities $390.9M$332.3M$356.2M$816.3M$873.3M$759.2M$564.9M$524.8M$157.0M$117.8M
Retained earnings $517.9M$556.4M$482.6M$481.2M$379.9M$326.5M$199.5M$86.5M-$26.8M-$84.3M
Total equity $1.06B$1.04B$921.5M$886.2M$815.9M$744.9M$595.4M$453.0M$267.5M$191.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $47.3M$172.0M$111.1M$116.8M$127.1M$138.4M$143.1M$129.0M$114.6M$66.8M
Depreciation and amortisation $91.6M$80.4M$84.9M$85.5M$32.6M$18.1M$6.7M$7.1M$8.1M$2.4M
Stock-based compensation $33.1M$27.8M$26.8M$17.6M$17.9M$16.6M$14.8M$11.3M$8.4M$5.9M
Capital expenditure $1.3M$725.0K$551.0K$412.0K—$3.4M$2.7M$844.0K$2.0M$1.6M
Investing cash flow $4.1M-$189.9M$268.7M-$216.7M-$81.9M-$34.7M-$157.9M-$413.5M-$86.4M-$36.0M
Financing cash flow $9.1M$12.2M-$397.9M-$10.5M-$130.4M$3.6M$3.9M$376.4M$5.7M$2.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-053111.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M 600M 800M Revenue, FY2016: 215M Gross profit, FY2016: 203M Net income, FY2016: 91.2M Revenue, FY2017: 302.2M Gross profit, FY2017: 287M Net income, FY2017: 57.3M Revenue, FY2018: 408.9M Gross profit, FY2018: 393.5M Net income, FY2018: 111M Revenue, FY2019: 392.8M Gross profit, FY2019: 376.1M Net income, FY2019: 113.1M Revenue, FY2020: 520.4M Gross profit, FY2020: 467.9M Net income, FY2020: 127M Revenue, FY2021: 579.8M Net income, FY2021: 53.4M Revenue, FY2022: 667.2M Gross profit, FY2022: 580M Net income, FY2022: 60.7M Revenue, FY2023: 607.5M Gross profit, FY2023: 523.7M Net income, FY2023: 1.3M Revenue, FY2024: 661.8M Gross profit, FY2024: 583.9M Net income, FY2024: 73.9M Revenue, FY2025: 719M Gross profit, FY2025: 644.4M Net income, FY2025: -38.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $215.0M $302.2M $408.9M $392.8M $520.4M $579.8M $667.2M $607.5M $661.8M $719.0M
Gross profit $203.0M $287.0M $393.5M $376.1M $467.9M — $580.0M $523.7M $583.9M $644.4M
Net income $91.2M $57.3M $111.0M $113.1M $127.0M $53.4M $60.7M $1.3M $73.9M -$38.6M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Results announced Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%